PL
BMRN icon

Parkwood LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Parkwood LLC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,202
Closed -$212K – 193
2023
Q4 		$212K Buy
+2,202
New +$195K 0.03% 122
2023
Q2 		– Sell
-3,560
Closed -$346K – 145
2023
Q1 		$346K Sell
3,560
-997
-22% -$103K 0.05% 128
2022
Q4 		$472K Buy
4,557
+972
+27% +$91.2K 0.07% 110
2022
Q3 		$304K Buy
3,585
+468
+15% +$41.7K 0.05% 128
2022
Q2 		$258K Sell
3,117
-388
-11% -$30.9K 0.05% 128
2022
Q1 		$270K Sell
3,505
-225
-6% -$18.8K 0.04% 119
2021
Q4 		$330K Sell
3,730
-279
-7% -$23K 0.06% 105
2021
Q3 		$310K Buy
4,009
+561
+16% +$44.3K 0.04% 108
2021
Q2 		$288K Sell
3,448
-1,110
-24% -$88K 0.03% 116
2021
Q1 		$344K Sell
4,558
-1,592
-26% -$130K 0.06% 102
2020
Q4 		$539K Buy
+6,150
New +$488K 0.07% 103

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Parkwood LLC's BMRN Position: Q1 2024 in Review

Parkwood LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 2,202 shares — an estimated $212K sold.

Parkwood LLC first reported a position in BMRN in Q4 2020 and held it in 11 quarters. The position peaked at $539K in Q4 2020. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Parkwood LLC reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Parkwood LLC sold 2,202 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $212K.
  • Parkwood LLC first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 11 quarters.
  • Parkwood LLC's BioMarin Pharmaceuticals position peaked at $539K in Q4 2020.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Parkwood LLC's 13F filing for Q1 2024, filed 15 May 2024.